<li>antithrombin alfa<p>antithrombin alfa, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>antithrombin iii<p>antithrombin iii, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>apixaban<p>clopidogrel and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug.</p></li><li>argatroban<p>argatroban, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>aspirin rectal<p>aspirin rectal increases effects of clopidogrel by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced risk of hemorrhage.</p></li><li>bivalirudin<p>bivalirudin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>cangrelor<p>cangrelor decreases effects of clopidogrel by receptor binding competition. Avoid or Use Alternate Drug. The expected antiplatelet effect of a 600 mg loading dose of clopidogrel was blocked when clopidogrel was administered during a cangrelor infusion. Therefore, clopidogrel should not be administered until cangrelor infusion is discontinued.</p></li><li>carbamazepine<p>carbamazepine will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>cimetidine<p>cimetidine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>clarithromycin<p>clarithromycin will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>dalteparin<p>dalteparin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>efavirenz<p>efavirenz decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>erythromycin base<p>erythromycin base will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A44 will reduce clopidogrel bioactivation </p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>erythromycin stearate<p>erythromycin stearate will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>esomeprazole<p>esomeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>etravirine<p>etravirine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>felbamate<p>felbamate decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>fluconazole<p>fluconazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>fluoxetine<p>fluoxetine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>fluvoxamine<p>fluvoxamine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>fondaparinux<p>fondaparinux, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>isoniazid<p>isoniazid decreases effects of clopidogrel by decreasing metabolism. Avoid or Use Alternate Drug. Cytochrome P450 2C19 inhibitors decrease the conversion of clopidogrel to its active form.</p></li><li>itraconazole<p>itraconazole will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>ketoconazole<p>ketoconazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>lepirudin<p>lepirudin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>modafinil<p>modafinil decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>omeprazole<p>omeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>oxcarbazepine<p>oxcarbazepine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>protamine<p>protamine, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>rabeprazole<p>rabeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19. .</p></li><li>repaglinide<p>clopidogrel will increase the level or effect of repaglinide by  Other (see comment). Avoid or Use Alternate Drug. Inhibits CYP2C8; concomitant use with repaglinide significantly increases repaglinide serum levels; when concomitant use required, initiate repaglinide at 0.5 mg with each meal and titrate based on blood glucose levels; not to exceed total daily dose of 4 mg repaglinide</p></li><li>rifabutin<p>rifabutin will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>rifampin<p>rifampin will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>selexipag<p>clopidogrel will increase the level or effect of selexipag by  increasing metabolism. Avoid or Use Alternate Drug. Coadministration of selexipag with strong CYP2C8 inhibitors may result in a significant increase in exposure to selexipag and its active metabolite. Avoid concomitant use.</p></li><li>st john's wort<p>st john's wort will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>ticlopidine<p>ticlopidine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>tinzaparin<p>tinzaparin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage.</p></li><li>voriconazole<p>voriconazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li>